Dr. Tristan Rousselle
Biography
Tristan Rousselle holds a Ph.D. in Cell Biology from the University Grenoble Alpes. He completed part of his postgraduate studies at Sussex University (Brighton, UK) and the La Jolla Institute for Allergy and Immunology (San Diego, CA). In 2000, he co-founded a company called Protein’eXpert, now known as PX’Therapeutics. This biotechnology company specializes in the engineering, pre-clinical, and clinical development of therapeutic proteins. By 2011, PX’Therapeutics had more than 60 employees in Grenoble and Lyon and generated nearly 50% of its turnover outside Europe.
In July 2013, a few months after the acquisition of PX Therapeutics by the “Laboratoire Aguettant,” Tristan decided to launch a new venture with a leading innovative project in the field of Biosensors
named “Aryballe”. He founded the company in March 2014. Since then, Tristan has successively held the positions of CEO, Deputy CEO & CTO (2018-2022), and President & CEO since November 2022. Over the last 10 years, Aryballe SA
has raised over $25M, open offices in New York and Seoul and has progressively become the leader in the growing industrial domain of Digital Olfaction.
Aryballe’s products are based on a smart combination of Silicon photonics sensors co-developed with the CEA, as well as fluidics, imaging, data science, and user-friendly software.
Company Profile
Aryballe
Aryballe combines biochemistry, advanced optics and machine learning to mimic the human sense of smell. Odors captured by the silicon photonics-based core sensor in our NeOse Advance are analyzed by the cloud-based Aryballe Suite to provide objective, fast analysis. This enables customers to leverage odor data for improved decision making for R&D, quality control, and manufacturing.